The opioid use disorder market size was exhibited at USD 5.87 billion in 2024 and is projected to hit around USD 16.89 billion by 2034, growing at a CAGR of 11.15% during the forecast period 2025 to 2034.
The U.S. opioid use disorder market size is evaluated at USD 3.04 billion in 2024 and is projected to be worth around USD 8.74 billion by 2034, growing at a CAGR of 10.7% from 2025 to 2034.
North America opioid use disorder market accounted for 68.98% share in 2024 due to several key factors. The region has the highest prevalence of OUD, which drives significant demand for treatment solutions. North America benefits from advanced healthcare infrastructure, extensive research and development capabilities, and a well-established network of healthcare providers and treatment facilities. Additionally, robust regulatory frameworks and substantial funding for addiction treatment programs support the development and distribution of effective therapies. The presence of leading pharmaceutical companies and a strong focus on innovative treatment approaches further contribute to North America's leadership in the OUD treatment market.
U.S. Opioid Use Disorder Market Trends
The U.S. opioid use disorder market is experiencing substantial growth due to increased awareness among healthcare professionals about available treatments and a rise in the prevalence of the disease. The CDC reports that over 131,778,501 opioid prescriptions were dispensed in the U.S. in 2022, with approximately 145,000 new OUD diagnoses that year.
Europe Opioid Use Disorder Market Trends
The European opioid use disorder market is undergoing significant transformation, driven by healthcare reforms, research advancements, and patient-centered initiatives across various countries. The rising prevalence of OUD, fueled by an aging population and evolving lifestyles, is increasing the demand for effective and innovative treatment options throughout the continent.
The UK opioid use disorder market is experiencing growth due to the rising prevalence of substance use disorders and expanding government initiatives to address the crisis. In the UK, over 50% of individuals with OUD are actively receiving treatment, with most undergoing Medications for Opioid Use Disorder (MOUD) such as methadone, buprenorphine, or naltrexone in 2023.
The France opioid use disorder market is poised for growth due to increasing awareness, government support, and evolving treatment options. As France addresses rising OUD prevalence with enhanced healthcare policies and expanded access to effective therapies, the market is set to expand significantly, driven by these supportive factors.
The Germany opioid use disorder market is marked by comprehensive treatment strategies and robust healthcare infrastructure. Enhanced by progressive regulations and increased funding for addiction services, Germany’s focus on integrated care and innovative therapies is driving significant growth and improving outcomes for individuals with opioid use disorder.
Asia Pacific Opioid Use Disorder Market Trends
The Asia Pacific opioid use disorder market is growing due to rising awareness, expanding healthcare infrastructure, and increasing prevalence of OUD. Countries in the region are implementing enhanced treatment programs and government initiatives to address the crisis. Improved access to effective therapies and ongoing research is driving market expansion. Additionally, growing collaborations between international and local organizations are fostering innovation and better management strategies, contributing to the accelerated development of the market and improved patient outcomes across the Asia Pacific region.
The China opioid use disorder market is growing at a rapid pace due to increasing awareness, expanding healthcare initiatives, and rising OUD cases. Enhanced treatment options and government support are driving market expansion, alongside efforts to improve access to effective therapies and address the growing demand for comprehensive addiction care.
The Japan opioid use disorder market is driven by rising awareness of addiction issues, government initiatives to improve treatment access, and advancements in healthcare infrastructure. Japan's focus on integrating innovative therapies and expanding support services is driving market growth. Additionally, efforts to address the increasing prevalence of OUD contribute to the market's expansion.
Latin America Opioid Use Disorder Market Trends
The Latin America opioid use disorder market is expanding due to growing awareness, increased government and NGO support, and advancements in treatment options. Rising opioid abuse and the need for effective therapies are driving market growth. Enhanced access to medications and improved healthcare initiatives across the region are further contributing to the market’s development.
The Brazil opioid use disorder market is significantly growing due to rising opioid abuse, increased government funding, and enhanced treatment programs. Expanded access to effective therapies and heightened awareness are driving this growth, alongside improved healthcare infrastructure and support services across the country.
MEA Opioid Use Disorder Market Trends
The Middle East & Africa (MEA) opioid use disorder market is expanding due to increasing awareness, government initiatives, and improved access to treatment. Rising opioid use and the development of healthcare infrastructure are driving growth, along with efforts to enhance support services and treatment options in the region.
The Saudi Arabia opioid use disorder market is poised to grow due to rising awareness, government initiatives, and enhanced healthcare services. Efforts to improve treatment access and expand support for recovery are driving market expansion, alongside increased focus on effective therapies and integrated care solutions in the region.
| Report Coverage | Details |
| Market Size in 2025 | USD 6.52 Billion |
| Market Size by 2034 | USD 16.89 Billion |
| Growth Rate From 2025 to 2034 | CAGR of 11.15% |
| Base Year | 2024 |
| Forecast Period | 2025-2034 |
| Segments Covered | Drug, Route of Administration, Distribution Channel, Region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional scope | North America; Europe; Asia Pacific; Latin America; MEA |
| Key Companies Profiled | Indivior PLC, Teva Pharmaceutical Industries, Ltd., Pfizer, Inc., Collegium Pharmaceutical (BioDelivery Sciences International, Inc.), Alkermes, Inc., Orexo US, Inc. (a part of Orexo AB), Titan Pharmaceuticals, Inc., Omeros Corporation, Camurus AB, Hikma Pharmaceuticals PLC |
Buprenorphine segment led the market and accounted for 59.58% of the global revenue in 2024 and is expected to grow at fastest CAGR over the forecast period. This is attributed due to its effective dual action as a partial opioid agonist, which helps alleviate withdrawal symptoms and cravings while minimizing euphoria and misuse risk. Its ceiling effect reduces overdose risk, and when combined with naloxone, it further deters abuse. A recent NIH-funded study from September 2024 indicates that adults with opioid use disorder who receive higher-than-recommended daily doses of buprenorphine may experience fewer behavioral health-related emergency department visits or inpatient services. These findings suggest that increased buprenorphine doses could enhance treatment outcomes, particularly for individuals using fentanyl, which significantly contributes to the ongoing overdose crisis. This research highlights the potential need to revisit dosing guidelines to better support effective management of opioid use disorder.
Naltrexone segment held the second largest revenue share of the market in 2024 due to its unique advantages. As a full opioid antagonist, naltrexone effectively blocks opioid receptors, preventing relapses by eliminating the euphoric effects of opioids. Its long-acting injectable form, Vivitrol, offers convenience with monthly dosing, improving patient adherence and reducing the risk of relapse. Naltrexone’s non-addictive nature and lack of abuse potential enhance its appeal compared to other treatments. Additionally, increasing awareness and expanding insurance coverage are likely to drive its adoption, contributing to its rapid market growth.
Injectable route of administration dominated the market and accounted for 59.26% of the global revenue in 2024 and is expected to grow at fastest CAGR rate over the forecast period. Extended release injectables, like Vivitrol (naltrexone) and Sublocade (buprenorphine), offer prolonged, steady drug delivery, improving adherence and reducing the risk of relapse. These formulations require less frequent administration typically monthly compared to daily oral medications, which enhances patient convenience and engagement. Injectable treatments also eliminate the risk of medication misuse or diversion, as they are administered by healthcare professionals. Additionally, the growing emphasis on patient-centered care and innovations in drug delivery systems are driving the adoption of injectables, positioning them as a rapidly expanding segment in OUD therapy.
The oral administration segment held the second largest revenue share in 2024. It is the most convenient and non-invasive method, which increases patient adherence and compliance. Oral medications such as buprenorphine and naltrexone are easier to administer and manage, requiring no specialized equipment or procedures. They also allow for flexible dosing and straightforward integration into daily routines. Additionally, oral medications can be taken at home, reducing the need for frequent clinic visits, thus improving accessibility and patient comfort. The established track record of oral formulations in effectively managing OUD, combined with their broad availability and ease of use, solidifies their leading position in the treatment landscape.
Hospital pharmacies dominated the market with a market share of 48.0% in 2024 due to their integral role in managing complex and severe cases. They offer a controlled environment where medications can be administered under strict supervision, which is crucial for ensuring adherence and safety, particularly for injectable and high-risk treatments. Hospital pharmacies also provide comprehensive patient care, including counseling and monitoring, which enhances treatment efficacy and supports recovery. Their ability to manage and distribute specialized medications, such as methadone and extended-release formulations, and their capacity for coordinating care with other healthcare services, solidify their dominant role in the distribution of OUD treatments. This central role in patient management and safety drives their prominence in the distribution channel.
Others segment is projected to witness a significant growth rate over the forecast period. The other pharmacies plays a critical role in the Opioid Use Disorder (OUD) market by expanding access to essential medications and treatment options. Online pharmacies, specialty clinics, and independent pharmacies provide critical avenues for individuals seeking convenient, discreet, and efficient access to OUD therapies. This segment is particularly significant for patients who may face barriers in reaching traditional brick-and-mortar pharmacies, such as those in rural or underserved areas. Online platforms offer home delivery, ensuring consistent adherence to medication regimens and minimizing disruptions in care.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the opioid use disorder market
By Drug
By Route Of Administration
By Distribution Channel
By Regional
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers